Compare IHRT & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IHRT | LBRX |
|---|---|---|
| Founded | 1974 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 552.6M | 602.6M |
| IPO Year | N/A | N/A |
| Metric | IHRT | LBRX |
|---|---|---|
| Price | $3.06 | $24.94 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $4.33 | ★ $49.00 |
| AVG Volume (30 Days) | ★ 502.2K | 145.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.98 | N/A |
| Revenue Next Year | $5.65 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.95 | $13.40 |
| 52 Week High | $5.44 | $24.95 |
| Indicator | IHRT | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.80 | 58.41 |
| Support Level | $3.01 | $22.48 |
| Resistance Level | $3.51 | $24.70 |
| Average True Range (ATR) | 0.18 | 1.32 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 53.17 | 84.65 |
iHeartMedia Inc is a United States-based audio media company. The company operates through the segments of the Multiplatform Group, the Digital Audio Group, and the Audio & Media Services Group. The company derives prime revenue from the Multiplatform Group segment which includes the company's Broadcast radio, Networks and Sponsorships, and Events businesses. The Digital Audio Group segment includes all of the company's digital businesses, including podcasting; and the Audio & Media Services Group includes Katz Media Group, a full-service media representation business, and RCS Sound Software, a provider of scheduling and broadcast software and services.
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.